secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001323885-26-000005
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q4 revenue $140.5M (+13.1% YoY); guides FY26 revenue $600-610M
-----------------------------------------------------------------------

- Q4 2025 revenue $140.5M (+13.1% YoY); net income $1.8M ($0.04 EPS) vs net loss $0.33 per share in Q4 2024.
- FY 2025 revenue $534.5M (+14.9% YoY); net loss $11.4M ($0.24 loss per share) improved from $0.95 loss per share in 2024.
- FY 2025 adjusted EBITDA $61.8M (+98% vs $31.1M in 2024); Q4 adj. EBITDA $19.9M vs $12.7M.
- FY 2026 guidance: revenue ~$600-610M (12-14% growth); adj. EBITDA $80-82M; positive net income; adj. EPS $0.09-0.15.
- U.S. revenue $435.4M (+13.7%); international $99.2M (+20.2%); growth driven by cryoSPHERE MAX, AtriClip FLEX-Mini, EnCompass clamp.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388526000005/0001323885-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388526000005/atrc-20260217.htm
  HTML page:      https://secwatch.observer/filing/0001323885-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer